GSK to Create Global Vax R&D Hub in Maryland; Consolidating Cambridge, Philly Sites

Apr 07, 2015


GSK has announced it is further expanding its vaccines presence in the U.S. by establishing a new global center for vaccines R&D in Rockville, Maryland.

The new site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D sites in Rixensart, Belgium and in Siena, Italy, a site which GSK acquired from Novartis as part of an asset swap deal that originated last April.

According to the GSK press release, the initiative will "consolidate vaccines R&D activities currently conducted at other GSK sites including in Philadelphia, PA and Cambridge, MA, into one centralized location."


Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments